Incyte Corporation (NASDAQ: INCY) and Abeona Therapeutics (NASDAQ:ABEO) are both biotechnology & medical research – nec companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.
Insider and Institutional Ownership
89.5% of Incyte Corporation shares are owned by institutional investors. Comparatively, 33.4% of Abeona Therapeutics shares are owned by institutional investors. 17.7% of Incyte Corporation shares are owned by insiders. Comparatively, 6.8% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Incyte Corporation and Abeona Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Incyte Corporation||$1.11 billion||20.12||$104.22 million||($0.80)||-131.78|
|Abeona Therapeutics||$890,000.00||760.44||-$21.87 million||($0.60)||-24.50|
Incyte Corporation has higher revenue and earnings than Abeona Therapeutics. Incyte Corporation is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Incyte Corporation has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500.
This table compares Incyte Corporation and Abeona Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Incyte Corporation and Abeona Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Incyte Corporation currently has a consensus price target of $144.90, suggesting a potential upside of 37.45%. Abeona Therapeutics has a consensus price target of $24.33, suggesting a potential upside of 65.53%. Given Abeona Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Incyte Corporation.
Incyte Corporation beats Abeona Therapeutics on 8 of the 13 factors compared between the two stocks.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.